ANVS · Annovis Bio, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $43.77M | $25.22M | $20M | $38.79M | $16.52M | $8.48M | $3.05M | $776.26K | |
| $5.76M | $4.48M | $6.7M | $6.24M | $9M | $6.06M | $3.59M | $829.37K | |
| $49.53M | $29.7M | $26.69M | $45.04M | $25.51M | $14.54M | $6.64M | $1.61M | |
| -$49.53M | -$29.7M | -$26.69M | -$45.04M | -$25.51M | -$14.54M | -$6.64M | -$1.61M | |
| $618.09K | $699.06K | $331.85K | $667.9K | — | — | — | — | |
| $6751 | $841.06K | $2.1M | -$11.17M | $182.71K | $50.09K | $1.18M | $614.64K | |
| -$40.94M | — | — | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$990.98K | |
| $0 | $0 | — | — | — | — | — | $0 | |
| -$49.52M | -$28.85M | -$24.59M | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$990.98K | |
| USD/shares | -$1.79 | -$1.40 | -$2.02 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | — |
| USD/shares | -$1.79 | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | — |
| shares | — | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M | 6.31M | 282.61K |
| shares | — | 20.55M | 12.24M | 9.02M | 8.16M | 7.63M | 6.31M | 282.61K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent convertible notes payable | 2019-12-31 | USD 499,807 | 10-K filed 2021-03-03 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 291 similar-size Biotechnology companies (of 531 listed).